Research has indicated that in the absence of PD-1/PD-L1 inhibitors, patients with high TMB have a worse survival rate, highlighting the clinical value of these inhibitors in improving survival and overcoming poor prognostic characteristics.[15] Furthermore, several studies have indicated that TMB levels are among the highest in NSCLC among various cancers, and TMB is emerging as a potential biomarker for predicting the efficacy of PD-1/PD-L1 inhibitors.[19]. The gene discussed is PDCD1; the disease is cancer.